News | Heart Valve Technology | February 10, 2016

Chicago Bulls’ Coach Fred Hoiberg Leads New Heart Valve Patient Education Campaign

NBA head coach shares personal experience as heart valve patient, receiving an On-X Aortic Heart Valve in 2015

Fred Hoiberg, Chicago Bulls coach, On-X aortic heart valve, education campaign

Fred Hoiberg, head coach of the NBA Chicago Bulls, is launching a new campaign to help people with heart valve problems on www.heartvalvesurgery.com. Coach Hoiberg, pictured here with his family, wanted a single, life-long solution to his aortic heart valve problem, and received an On-X aortic mechanical valve from On-X Life Technologies Inc. in April 2015.

On-X Aortic Heart Valve, Fred Hoiberg, Chicago Bulls

The On-X Aortic Heart Valve from On-X Life Technologies Inc. is the only mechanical heart valve FDA-cleared to allow patients to reduce blood thinner medication to nearer normal levels.

February 10, 2016 — Fred Hoiberg, head coach of the National Basketball Assocation’s (NBA) Chicago Bulls, is launching a new patient education campaign featuring a video recounting his experience as a heart valve patient. The video premiered January 14 on www.HeartValveSurgery.com.

A 10-year NBA veteran who had played for the Indiana Pacers, Chicago Bulls and Minnesota Timberwolves, Hoiberg had open-heart surgery in April 2015 to replace his failing bicuspid aortic heart valve, a heredity structural malformation that had been causing increasing fatigue and shortness-of-breath.

The campaign, designed to help people with heart valve problems learn more about their condition and treatment options, is sponsored by On-X Life Technologies Inc., the company that made Coach Hoiberg’s aortic replacement heart valve. The full video is available here.

Hoiberg, who had an open-heart surgery a decade earlier to address life-threatening problems with an aortic aneurysm, was seeking a single, life-long solution to his aortic valve problem and agreed when his doctor recommended he receive an On-X Aortic Heart Valve.

“The On-X valve is expected to last throughout my lifetime, so I don’t have to worry about the possibility of future re-operations, which would have been likely if I’d received a tissue valve,” Hoiberg said. “I also didn’t want to put my family through all of the stress related to needing additional surgeries in the future.”

“Tissue valves last longer in older people and are less durable in younger people, and there are risks with every subsequent reoperation for valve failure,” said Marc Gerdisch, M.D., chief of cardiovascular and thoracic surgery at Franciscan St. Francis Heart Center in Indianapolis.

“If Coach Hoiberg had, at his age and physical activity level, received a tissue valve instead of the On-X aortic heart valve, he’d likely have needed another one, and even another one after that during his lifetime,” Gerdisch said, adding that most tissue valves are documented to fail structurally in 15 years or fewer in patients younger than age 60.

While some patients may choose replacement valves made of animal tissue in hopes of avoiding taking the blood-thinning medication warfarin, many patients also require warfarin therapy in order to manage their other health conditions, such as atrial fibrillation (AFib).

“I’ve heard that some people have concerns about taking blood-thinning medication after getting a mechanical valve, but it hasn’t been an issue for me. I’m very physically active, yet I haven’t had to make any major changes in either my activities or my diet because I’m taking blood-thinners,” said Hoiberg.

Gerdisch added that patients with On-X aortic heart valves are the only ones in the United States who have been allowed by the U.S. Food and Drug Administration (FDA) to reduce their blood-thinning medications to “near normal” levels.

“In a multi-year clinical study, we demonstrated that patients who had received an On-X aortic heart valve could be safely and effectively managed at much lower levels of blood thinner medication. Our findings showed that there are significant reductions in complications with the On-X valve when compared to any other valve, whether mechanical or tissue,”1 said Gerdisch, who also served as a principal investigator of the PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) study. “The On-X valve is a genuine innovation and the only mechanical valve that I implant.”

On-X replacement heart valves are bileaflet prosthetic valves made of pure pyrolytic carbon. Clinical evaluations have shown that the On-X Aortic Heart Valve features a unique material and design, which have been clinically documented to have lower complications than other mechanical heart valves.

For more information: www.onxvalve.com

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Overlay Init